H1N1 seasonal influenza virus vaccine - Vaxart

Drug Profile

H1N1 seasonal influenza virus vaccine - Vaxart

Alternative Names: Ad-HA-dsRNA; Seasonal influenza vaccine - Vaxart; VXA-A1.1

Latest Information Update: 26 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vaxart
  • Class Influenza A virus H1N1 vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza A virus H1N1 subtype

Most Recent Events

  • 31 Mar 2017 Vaxart initiates enrolment in a phase I trial for Influenza-A virus H1N1 subtype in USA (NCT03121339)
  • 01 Aug 2016 Phase-II clinical trials in Influenza-A virus H1N1 subtype (Prevention) in USA (PO, Tablet) (NCT02918006)
  • 21 Apr 2016 No development reported - Phase-I for Influenza-A virus H1N1 subtype (Prevention) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top